You just read:

US Rheumatologists' Early Views on Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer's Xeljanz Holds Ground as the Preferred JAK Inhibitor

News provided by

Spherix Global Insights

Aug 20, 2018, 13:50 ET